Anti-Human Prolactin R Reference Antibody (XOMA 213, RUO) (HB801056)

Name: Anti-Human Prolactin R Reference Antibody (XOMA 213, RUO)
Brand: abinScience
SKU: HB801056
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HB801056
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG
ID de clone	XOMA 213
Activité biologique	XOMA-213 (10 ug/mL) specifically binds to endogenous human and rat PRLR expressed on the surface of T47D, MCF7, Nb2-11, BaF3/hPRLR cells and primary human breast tumor cells, but does not bind to mouse PRLR or PRLR-negative BaF3 cells [1]. XOMA-213 (0.01-10 ug/mL; pre-incubated on ice for 45 min) binds to T47D cells without interfering with the PRL-PRLR interaction, exhibiting a non-ligand competitive binding mode [1]. XOMA-213 (0.05-10 ug/mL; 30 min pre-incubation at 37°C) potently inhibits hPRL-induced phosphorylation of Stat5, Akt and ERK1/2 in T47D cells, suppresses hPRL-induced Stat5 phosphorylation in MCF7 cells, and completely blocks hPRL-induced Stat5 phosphorylation in ER+/PR+/HER2- primary human breast tumor cells, with no detectable agonist activity [1]. XOMA-213 (0.01-100 ug/mL; 96-168 h) completely blocks hPRL-induced proliferation of T47D cells, potently inhibits the survival of Nb2-11 cells, suppresses hPRL- and hGH-induced proliferation in BaF3/hPRLR cells (EC 50 = 0.5 ug/mL), and inhibits autocrine PRL-dependent growth in BaF3/hPRLR/hPRL cells. It performs better than ligand-competitive antagonists in high-ligand environments [1]. XOMA-213 (0.001-100 ug/mL; 24 h) induces antibody-dependent cell-mediated cytotoxicity (ADCC) against T47D cells, with a maximum cell killing rate of 50% and an EC 50 of 0.13 ug/mL, demonstrating an additional antitumor mechanism of action [1]. Western Blot Analysis [1] Cell Line: T47D human ER+ breast cancer cells, MCF7 human ER+ breast cancer cells, dissociated primary human breast tumor cells (ER+/PR+/HER2-) Concentration: 0.05, 0.1, 0.5, 1, 5 ug/mL (T47D/MCF7 cells); 10 ug/mL (primary tumor cells); 50 ng/mL hPRL Incubation Time: 30 min (pre-incubation at 37°C); 30 min (hPRL stimulation) Result: Neutralized hPRL-induced phosphorylation of Stat5, Akt, and ERK1/2 in a concentration-dependent manner in T47D cells. Antagonized hPRL-induced Stat5 phosphorylation efficiently in MCF7 cells.
Système d'expression	Mammalian cells
Cible	PRLR, PRL-R, Prolactin receptor
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P16471
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	XOMA-213, XOMA213, XOMA213
Contexte	Prolactin receptor (PRLR) is a ~69 kDa protein. This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. Isoform 6 is unable to transduce prolactin signaling.
Reférences	1. Damiano JS, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther. 2013;12(3):295-305. [HB801056]
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)